Omnix Medical Starts Phase I Clinical Trial of their Novel Antimicrobial Agent
New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April XX, 2022 —
FDA Clearance to Gamida Cell for GDA-201 Treatment of Follicular & Diffuse Large B Cell Lymphomas
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in nicotinamide (NAM) -enabled cell therapies for patients with hematologic and solid cancers, has received the green light
Olive Diagnostics AI Urine Analysis Readable on The Apple Watch
Jerusalem-based Olive Diagnostics’s KG system is the world’s first 100 percent passive non-invasive real-time urine analysis sensor that can be hooked up to any toilet. This
KAHR Published Preclinical Data Indicating Treatment Potential of Their Anti-CD47 Fusion Protein
KAHR, a Jerusalem clinical-stage cancer immunotherapy company, has just announced the publication of their preclinical data that supports the development of DSP107. DSP107 is a
Salignostics Closes $8M Funding Round to Take Its Saliva-Based Pregnancy Test to Market
Salignostics, a Jerusalem medical startup, has raised $8 million in a Series A financing round in order to mass market their rapid saliva-based test kits.
Nectin Therapeutics Obtained $5.4 Million Investment for Solid Tumors Immunotherapy Study
Nectin Therapeutics Ltd., a biotechnology company developing novel targeted immunotherapies, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University
NewStem Files FDA Pre-Submission & EMA IVDD for Revolutionary Cancer Diagnostic Device
NewStem Ltd filed for a pre-submission to the FDA for a De Novo Request and an in vitro cancer diagnostic device (IVDD) to the EMA
Nanox Opens So. Korean Fab Plant to Produce Semiconductor Chips for Novel Digital Nanox.ARC 3D X-Ray System
Nanox (Nasdaq/TASE: ), an Israeli corporation that has developed the first solid-state digital X-ray source designed to be used in real-world medical imaging applications, has
Oramed Granted NASH Patent in Europe
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office
